Wedbush Issues Negative Outlook for Zenas BioPharma Earnings

Key Points

• Wedbush has reduced its Q3 2025 EPS estimate for Zenas BioPharma to ($1.33) per share, down from a previous estimate of ($1.04), while maintaining an "Outperform" rating and a target price of $35.00.
• The company's stock opened at $16.76, with a market cap of approximately $705.76 million and a PE ratio of -4.72.
• Zenas BioPharma missed analysts' consensus estimates for the most recent quarter, reporting ($1.25) EPS compared to expectations of ($1.02).

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) - Stock analysts at Wedbush cut their Q3 2025 earnings estimates for Zenas BioPharma in a research note issued to investors on Tuesday, August 12th. Wedbush analyst M. Fan now anticipates that the company will post earnings of ($1.33) per share for the quarter, down from their prior estimate of ($1.04). Wedbush has a "Outperform" rating and a $35.00 price target on the stock. Wedbush also issued estimates for Zenas BioPharma's Q4 2025 earnings at ($1.13) EPS, FY2025 earnings at ($4.51) EPS, Q1 2026 earnings at ($1.14) EPS, Q2 2026 earnings at ($1.15) EPS, Q3 2026 earnings at ($1.17) EPS, Q4 2026 earnings at ($1.18) EPS, FY2026 earnings at ($4.64) EPS, FY2027 earnings at ($4.41) EPS, FY2028 earnings at ($3.02) EPS and FY2029 earnings at ($1.20) EPS.

Several other analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Zenas BioPharma from a "hold" rating to a "sell" rating in a report on Saturday. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of Zenas BioPharma in a report on Friday, May 16th.

Zenas BioPharma Trading Up 2.7%

ZBIO stock traded up $0.46 during trading on Friday, reaching $17.28. 329,359 shares of the company were exchanged, compared to its average volume of 126,694. Zenas BioPharma has a 52-week low of $5.83 and a 52-week high of $26.25. The firm's 50 day moving average is $12.85.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($1.25) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.23).

Hedge Funds Weigh In On Zenas BioPharma

Several institutional investors and hedge funds have recently modified their holdings of ZBIO. Federated Hermes Inc. lifted its stake in shares of Zenas BioPharma by 60.8% during the second quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company's stock valued at $18,041,000 after buying an additional 703,838 shares during the period. Jefferies Financial Group Inc. purchased a new position in shares of Zenas BioPharma during the first quarter valued at approximately $348,000. Nuveen LLC purchased a new position in shares of Zenas BioPharma during the first quarter valued at approximately $250,000. Geode Capital Management LLC lifted its stake in shares of Zenas BioPharma by 4.6% during the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company's stock valued at $3,621,000 after buying an additional 16,461 shares during the period. Finally, Sei Investments Co. purchased a new position in shares of Zenas BioPharma during the second quarter valued at approximately $118,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.